New hope for advanced cancer: MHB048C enters human trials
NCT ID NCT07192120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MHB048C in 200 adults with advanced solid tumors (like prostate cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV, and researchers monitor side effects and tumor changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can your own immune cells beat advanced cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?